Why Jim Cramer Would Buy AbbVie (ABBV), St. Jude Medical (STJ) Stock on Tax Inversion News

NEW YORK (TheStreet) -- TheStreet's Jim Cramer is not happy about the Treasury Department's announced revisions to the U.S. tax code that would discourage U.S. companies from performing tax inversion deals by merging with foreign companies and moving their headquarters outside the U.S.

Cramer asked Secretary of the Treasury Jack Lew in July if he could do anything to stop inversions, and Lew said the law did not allow his department to change anything and that it was up to Congress. But on Monday, the Treasury Department and the IRS announced the changes to the code to stop the inversions.

Cramer says he finds this ridiculous but theorizes this could be a gambit to get comprehensive legislation through Congress. But he notes that the government's announcement is causing tremendous havoc in the stock market.

Must Watch: Jim Cramer's Take on Lew's Crackdown of Corporate Tax Inversions

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The only company Cramer would buy off this news is AbbVie  (ABBV) because he thinks it is a good company that would work either way. Medtronic  (MDT) and Covidien (COV) are also coming down, but Cramer says he likes St. Jude Medical  (STJ) .

 

ABBV Chart ABBV data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

AbbVie Is Likely to Correct: Book Some Profits

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst